Subconjunctival methotrexate in the treatment of non infectious ocular inflammatory diseases

SUMMARY We studied the effect of subconjunctival injections of methotrexate (MTX) in 18 patients with non-infectious ocular inflammatory processes (unilateral anterior uveitis 11 patients, corneal graft rejection 3 patients, nodular sclerouveitis with no systemic disease 2 patients, Vogt-Koyanagi-Ha...

Full description

Bibliographic Details
Main Authors: Seiji Hayashi, Rubens Belfort Jr
Format: Article
Language:English
Published: Conselho Brasileiro de Oftalmologia
Series:Arquivos Brasileiros de Oftalmologia
Subjects:
Eye
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27491997000300303&lng=en&tlng=en
id doaj-8f1175ae3bf94e8c80daf113e0fc4834
record_format Article
spelling doaj-8f1175ae3bf94e8c80daf113e0fc48342020-11-24T21:40:08ZengConselho Brasileiro de OftalmologiaArquivos Brasileiros de Oftalmologia1678-292560330330710.5935/0004-2749.19970065S0004-27491997000300303Subconjunctival methotrexate in the treatment of non infectious ocular inflammatory diseasesSeiji HayashiRubens Belfort JrSUMMARY We studied the effect of subconjunctival injections of methotrexate (MTX) in 18 patients with non-infectious ocular inflammatory processes (unilateral anterior uveitis 11 patients, corneal graft rejection 3 patients, nodular sclerouveitis with no systemic disease 2 patients, Vogt-Koyanagi-Harada's disease 1 patient, and Behcet's disease 1 patient). Weekly subconjunctival injections of 7.5mg of MTX were given. Daily slit lamp examination was performed to evaluate the degree of inflammatory activity in the anterior chamber or sclera and conjunctiva during the treatment. Patients were clinically followed for an average of 7.8 months (3 to 12 months) and no patient had evidence of local or systemic side effects. The conjunctiva remained yellowish and edematous for approximately 24hs after the injections and returned to the previous aspect after that. Our results showed that subconjunctival weekly injections oflow dose MTX have a favorable response in the treatment in nine of 11 cases of anterior uveitis, three cases of corneal graft rejection, and one patient of Vogt-Koyanagi-Harada disease. One patient with Behcet disease, and two with scleritis did not respond to the treatment.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27491997000300303&lng=en&tlng=enMethotrexateEyeUveitisInflammationImmunosuppressionDrug
collection DOAJ
language English
format Article
sources DOAJ
author Seiji Hayashi
Rubens Belfort Jr
spellingShingle Seiji Hayashi
Rubens Belfort Jr
Subconjunctival methotrexate in the treatment of non infectious ocular inflammatory diseases
Arquivos Brasileiros de Oftalmologia
Methotrexate
Eye
Uveitis
Inflammation
Immunosuppression
Drug
author_facet Seiji Hayashi
Rubens Belfort Jr
author_sort Seiji Hayashi
title Subconjunctival methotrexate in the treatment of non infectious ocular inflammatory diseases
title_short Subconjunctival methotrexate in the treatment of non infectious ocular inflammatory diseases
title_full Subconjunctival methotrexate in the treatment of non infectious ocular inflammatory diseases
title_fullStr Subconjunctival methotrexate in the treatment of non infectious ocular inflammatory diseases
title_full_unstemmed Subconjunctival methotrexate in the treatment of non infectious ocular inflammatory diseases
title_sort subconjunctival methotrexate in the treatment of non infectious ocular inflammatory diseases
publisher Conselho Brasileiro de Oftalmologia
series Arquivos Brasileiros de Oftalmologia
issn 1678-2925
description SUMMARY We studied the effect of subconjunctival injections of methotrexate (MTX) in 18 patients with non-infectious ocular inflammatory processes (unilateral anterior uveitis 11 patients, corneal graft rejection 3 patients, nodular sclerouveitis with no systemic disease 2 patients, Vogt-Koyanagi-Harada's disease 1 patient, and Behcet's disease 1 patient). Weekly subconjunctival injections of 7.5mg of MTX were given. Daily slit lamp examination was performed to evaluate the degree of inflammatory activity in the anterior chamber or sclera and conjunctiva during the treatment. Patients were clinically followed for an average of 7.8 months (3 to 12 months) and no patient had evidence of local or systemic side effects. The conjunctiva remained yellowish and edematous for approximately 24hs after the injections and returned to the previous aspect after that. Our results showed that subconjunctival weekly injections oflow dose MTX have a favorable response in the treatment in nine of 11 cases of anterior uveitis, three cases of corneal graft rejection, and one patient of Vogt-Koyanagi-Harada disease. One patient with Behcet disease, and two with scleritis did not respond to the treatment.
topic Methotrexate
Eye
Uveitis
Inflammation
Immunosuppression
Drug
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27491997000300303&lng=en&tlng=en
work_keys_str_mv AT seijihayashi subconjunctivalmethotrexateinthetreatmentofnoninfectiousocularinflammatorydiseases
AT rubensbelfortjr subconjunctivalmethotrexateinthetreatmentofnoninfectiousocularinflammatorydiseases
_version_ 1725927942798704640